Completed PHASE4 INTERVENTIONAL 2-arm NCT01017029

Everolimus in de Novo Heart Transplant Recipients (EVERHEART)

Early vs. Delayed EVERolimus in de Novo HEART Transplant Recipients: Optimization of the Safety/Efficacy Profile (EVERHEART Study)

Sponsor: Novartis Pharmaceuticals

Conditions Cardiac Transplantation

Interventions Everolimus Mycophenolate mofetil + Everolimus

Updated 7 times since 2017 Last updated: Dec 23, 2014 Started: Sep 30, 2009 Primary completion: Dec 31, 2013 Completion: Dec 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01017029, this PHASE4 trial focuses on Cardiac Transplantation and remains completed. Sponsored by Novartis Pharmaceuticals, it has been updated 7 times since 2009, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE4
Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Sep 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bari, Italy , Bologna, Italy , Cagliari, Italy , Milan, Italy , Napoli, Italy , Padua, Italy , Pavia, Italy , Roma, Italy , Siena, Italy , Torino, Italy and 2 more locations